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Mammalian type C retrovirus enhancer factor 1 (MCREF-1) is a nuclear protein that binds several directly
repeated sequences (CNGGN6CNGG) in the Moloney and Friend murine leukemia virus (MLV) enhancers
(N. R. Manley, M. O'Connell, W. Sun, N. A. Speck, and N. Hopkins, J. Virol. 67:1967-1975, 1993). In this
paper, we describe the partial purification of MCREF-1 from calf thymus nuclei and further characterize the
binding properties of MCREF-1. MCREF-1 binds four sites in the Moloney MLV enhancer and three sites in
the Friend MLV enhancer. Ethylation interference analysis suggests that the MCREF-1 binding site spans two
adjacent minor grooves of DNA.

protein known under several aliases, including the polyomavirus enhancer binding factor 2 (PEBP2) (35), the SL3
enhancer factor 1 (SEF1) (40), the SL3 and AKV core
binding factor (S/A-CBF) (3), and, simply, core binding
factor (CBF) (42).
In the accompanying paper, we describe a protein in crude
nuclear extracts that binds sequences in both the LVb and
core sites, called mammalian type C retrovirus enhancer
factor 1 (MCREF-1) (28). MCREF-1 also binds several
sequences in the Friend MLV enhancer: the Friend virus
factor a (FVa) and FVbl sites, three sequences in the
Moloney MLV enhancer, and one site in the GC-rich region
immediately 3' to the Moloney MLV enhancer direct repeat.
Here we describe the partial purification of MCREF-1 from
calf thymus and further characterize the binding properties
of MCREF-1.

The murine type C retroviruses cause a variety of different
diseases in their infected hosts. Multiple regions of the
retroviral genome determine the pathogenic phenotype of a
virus, and many investigators have identified viral genetic
determinants that influence pathogenesis and continue to
study the mechanisms by which these genetic regions exert
their effects. One viral genetic determinant that has been
shown in a number of studies to influence pathogenesis is the
retroviral enhancer. In several replication-competent murine
leukemia viruses (MLVs), the enhancer has been shown to
influence such properties as the leukemogenicity of the
virus, the latent period of disease onset, the organ tropism,
and the disease specificity (5, 6, 8-11, 18, 26, 27).
An 18-bp sequence is particularly well conserved among
mammalian type C retroviral enhancers [AAACAGGATA
TCTG(T/C)GGT] (14). This sequence contains both the
leukemia virus factor b (LVb) site (CAGGAT) and the core
site [TG(T/C)GGT] (38). The LVb and core sites are important viral genetic determinants for pathogenesis of the SL3-3
MLV and Moloney MLV. Point mutations introduced into
the core site in both the SL3-3 and Moloney MLV enhancers
increased the latent period of disease onset by these viruses
and, in the case of Moloney, altered disease specificity from
thymic to predominantly erythroid leukemia (17, 39). Mutations in the LVb site in the Moloney MLV also caused an
increase in the latent period and a small shift in disease
specificity to erythroleukemia (39).
The LVb site was originally defined as the binding site for
a protein found in crude B-cell nuclear extracts, LVb. It
soon became apparent that more than one protein binds to
the LVb site; thus, in this paper we use the name LVb to
define a DNA sequence (CAGGAT) within the enhancer.
The LVb site binds the Ets proteins Ets-1 and Ets-2 (15, 34)
as well as a protein called LVt (28). The adjacent core site
was first identified as a conserved sequence element in
several viral enhancers (43); it also binds multiple proteins,
including the CAAT/enhancer binding protein (C/EBP) (20),
activating protein 3 (AP3) (32), SL3 core binding factor
(S-CBF) (3), AKV core binding factor (A-CBF) (3), and a

MATERIALS AND METHODS
Biochemical assays. (i) Substrates for protein binding in
electrophoretic mobility shift assays. The origins of the oligonucleotides from the Moloney and Friend MLV enhancers
that were used in biochemical assays are shown in Fig. 1,
and the sequences are listed in Table 1. Complementary
oligonucleotides were synthesized with the Biosearch Cyclone DNA Synthesizer at Dartmouth Medical School and
an Autogen 6500 DNA synthesizer at the Center for Cancer
Research, Massachusetts Institute of Technology. All oligonucleotides were purified by electrophoresis through 20%
polyacrylamide-7 M urea gels.
Radioactive probes were made by labeling 100 pmol of one
oligonucleotide, either the plus or minus strand of the
binding site, with [-y-32P]ATP (7,000 Ci/mmol; ICN) and T4
polynucleotide kinase (New England Biolabs) and then
annealing the labeled oligonucleotide with 100 pmol of its
complementary strand (23). The double-stranded probes
were then purified by electrophoresis through 20% native
polyacrylamide gels. The specific activity of the probes was
typically 4,000 to 10,000 cpm/fmol.
Competitor oligonucleotides were prepared by annealing
equimolar amounts of unlabeled complementary oligonucleotides. The annealed oligonucleotides were used directly as
competitors in binding reactions.
(ii) Protein-DNA binding analysis. MCREF-1 binding ac-
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FIG. 1. Origins of oligonucleotides from the Moloney and Friend MLV enhancers used to detect MCREF-1. The upper portion of the
figure is a schematic representation of the Moloney and Friend MLV long terminal repeat, showing the location of the enhancer direct repeat
(DR) and adjacent GC-rich region. The sequences underneath are from the second copy of the direct repeat of the Moloney (MO) and Friend
(FR) enhancers. Numbering of the Moloney MLV enhancer sequence is from the cap site at the 5' end of the viral genome, and the Friend
MLV enhancer is numbered from the 5' end of the env gene, both by the numbering of Weiss et al. (44). Asterisks between the Moloney and
Friend enhancer sequences indicate positions of sequence divergence. Dashes within the sequence indicate gaps in the alignment between the
two enhancers. Binding sites for nuclear factors (NFla and NFlb, designating the sites 5' and 3' to the LVb site, respectively; LVb; the core
site; LVc; and sites for FVa and FVb1) are indicated by horizontal boxes above the sequence (29, 38). The 5' and 3' boundaries of the
oligonucleotides used in the analysis derived from the Moloney virus enhancer are indicated by horizontal lines above the Moloney enhancer
sequence. Oligonucleotides derived from the Friend MLV enhancer are shown below the Friend enhancer sequence. The LVb-core
oligonucleotides are derived from sequences that are conserved between the Moloney and Friend MLV enhancers. Oligonucleotides
containing point mutations in the LVb or core binding sites and an alteration in the 3' end of the FVb1 site are indicated by the substituted
nucleotide within the horizontal line.

was detected by the electrophoretic mobility shift
(12, 13, 37). Binding reactions contained 10,000 cpm (2
to 5 fmol) of 32P-end-labeled probe, binding buffer (100 mM
NaCl, 10 mM Tris [pH 7.4], 1 mM ,-mercaptoethanol, 1 mM
EDTA, 4% glycerol), 0.2 to 1.0 ,ug of poly(dI-dC)-poly(dIdC) (Pharmacia), and 1 to 10 ,ul of protein sample, in a total
volume of 15 ,ul. To demonstrate the sequence specificity of

tivity

assay

the protein-DNA complex, various amounts of unlabeled
oligonucleotides were included in some of the binding reactions. After 15 min of incubation at room temperature, the
reaction mixtures were fractionated by electrophoresis
through a 5 to 6% native polyacrylamide gel containing 0.5 x
TBE (22.5 mM Tris-HCl, 22.5 mM boric acid, 0.5 mM
EDTA). Radioactivity was detected by autoradiography of

TABLE 1. Sequences of oligonucleotides used in the biochemical assays
Name

Sequence

LVb/core A
LVb/core B
LVb/core C
LVb/core D
LVb/core E

CCAAACAGGATATCTGTGGTAAGCA

MVa
MVb
FVa
FVbl
MVc
FVc
Ad-NF1

AACAGATGGAACAGCTGAATATGGGCCAAACAGGATATCTG
CAGTTCCTGCCCCGGCTCAGGGCCAAGAA
AACAGATACGCTGGGCCAAACAGGATATCTG

a

CCAAACAGGATATCTGTGTTAAGCA
CCAAAMGGATATCTGTGGTAAGCA

Source

Coordinates

Moloney
Friend

7949-7973,8024-8048
2914-2938,2979-3003

Moloney
Moloney

7923-7963,7999-8039
7972-8000,8047-8075

CCAAACATIATATCTGTGGTAAGCA

CCAAACAGGATATCTTTGGTAAGCA

CAGTTTCGGCCCGGTCGGOCCCCGGCCCGAGaa

Friend
Friend

CCCCAGATGCGGTCCAGCCCTCAGCAGTTTCTAGAGA
Moloney
Friend
CCCCAGATATGGCCCAACCCTCAGCAGTTTCTTAAGA
Ad2a
TTTTGGATTGAAGCCAATATGAG
Adenovirus type 2 origin of replication, with point mutation at +28, as described by Chodosh et al. (7).

2964-2994
3002-3031

8085-8120
3048-3084
+22-+44 (left terminus)
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the dried gel. The amount of DNA in specific protein-DNA
complexes was quantified by scintillation spectrometry of
the protein-DNA complex bands excised from dried polyacrylamide gels, counted in the presence of Ecoscint A
(National Diagnostics).
Partial purification of MCREF-1. (i) Preparation of nuclear
extracts. Nuclear extracts were prepared from previously
frozen calf thymus as described by Wang and Speck (42),
with the following modification: after extracting proteins
from the nuclear pellet in buffer E (250 mM sucrose, 400 mM
NaCl, 50 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid [HEPES; pH 7.5], 10 mM 13-mercaptoethanol,
1 mM phenylmethylsulfonyl fluoride) and collecting the
nuclei by centrifugation, the proteins in the supernatant were
precipitated from the nuclear extract by slow addition of
ammonium sulfate to a final concentration of 35%, instead of
50% as reported previously for CBF (42). MCREF-1 was
quantitatively precipitated with 0 to 35% ammonium sulfate
(data not shown). The ammonium sulfate precipitate was
collected by centrifugation, resuspended, and dialyzed
against buffer B (50 mM NaCl, 20 mM HEPES [pH 7.5], 10
mM P-mercaptoethanol, 2 mM EDTA, 10% glycerol), as
described previously (42). Typical yields were 0.5 g of
nuclear extract per 100 g of calf thymus tissue.
(ii) DE52 chromatography. The resuspended and dialyzed
0 to 35% ammonium sulfate precipitate (2,200 mg of protein)
was applied directly to a DE52 cellulose (Whatman) column
(2.5 by 20 cm, 100 ml) that was equilibrated in buffer B. The
column was washed with 3 column volumes of buffer B and
then developed with a linear gradient of [NaCl] from 50 mM
to 1.0 M in buffer B. Fractions (10 ml) were collected and
assayed for MCREF-1 activity by electrophoretic mobility
shift assays. Fractions were also analyzed for protein concentration and [NaCI]. Protein concentrations were determined by the method of Bradford (4) with reagents purchased from Bio-Rad. The concentration of NaCl in column
fractions was determined by measuring conductivity in comparison to a standard curve.
Active fractions were pooled and dialyzed against buffer B
(50 mM NaCI). The DE52 cellulose resin was regenerated
with 5 column volumes of buffer B plus 2.5 M NaCl.
(iii) Heparin-Sepharose chromatography. Dialyzed pooled
fractions from the DE52 column were applied onto a heparin-Sepharose column (2.5 by 13 cm, 70 ml) that was
equilibrated with buffer B. The column was washed with 3
column volumes of buffer B and then developed with a
500-ml linear gradient of [NaCl] from 50 mM to 1.0 M in
buffer B. Approximately 5.5-ml fractions were collected.
Fractions were analyzed for MCREF-1 activity, protein
concentration, and [NaCl]. Fractions with MCREF-1 activity were pooled and dialyzed against buffer B. HeparinSepharose was regenerated according to the manufacturer
(Pharmacia).
Recovery and renaturation of protein from SDS-polyacrylamide gels. Sodium dodecyl sulfate (SDS)-polyacrylamide
gel electrophoresis (PAGE) was performed as described by
Laemmli (25). Protein samples (3 ml, 3.75 mg of protein)
were precipitated with 9.1% trichloroacetic acid in the
presence of 0.14 mg of deoxycholate per ml as a carrier.
Denaturation-renaturation experiments were performed as
described by Hager and Burgess (16), with several modifications. Following electrophoresis through a 9.3-cm
SDS-8% polyacrylamide gel, the lanes containing the molecular weight markers were excised from the gel and stained
with Coomassie brilliant blue. The remainder of the gel was
then sliced from top to bottom into 22 equal 4.2-mm slices,
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and each slice was then chopped into smaller pieces. Proteins were eluted from each gel slice by incubation in 200 to
300 ,ul of a buffer containing 150 mM NaCl, 20 mM HEPES
(pH 7.5), 5 mM dithiothreitol, 0.1 mM EDTA, 0.1% SDS,
and 0.1 mg of bovine serum albumin per ml overnight at
room temperature. The eluted protein was precipitated with
4 volumes of cold (-20°C) acetone and collected by centrifugation (16,000 x g for 30 min). The pellet was washed with
a solution containing 80% acetone-20% dilution buffer (150
mM NaCl, 20 mM HEPES [pH 7.5], 1 mM dithiothreitol, 0.1
mM EDTA, and 20% glycerol), dried, dissolved in 5 ,ul of
dilution buffer supplemented with 6 M guanidine-HCl, and
incubated at room temperature for 30 min. The protein was
then renatured by dilution with 250 ,ul of dilution buffer
without guanidine-HCl at 4°C overnight. Ten microliters of
each protein sample was assayed for MCREF-1 binding
activity by electrophoretic mobility shift assay, in the presence of 0.1 ,ug of poly(dI-dC)-poly(dI-dC) (the protein eluted
from the last [bottom] slice, slice 22, was not tested for
binding activity).
Methylation and ethylation interference analyses. Binding
reaction mixtures for methylation interference analysis (75
,ul total volume) contained 100,000 cpm of end-labeled,
methylated (31) probe, 1 to 5 ,ug of poly(dI-dC)-poly(dI-dC),
15 pl (19 ,ug) of partially purified protein from pooled
fractions from the heparin-Sepharose column, and 250 ng of
unlabeled, nonspecific competitor DNA (LVb/core D [Fig. 1
and Table 1]) in the same binding buffer used for electrophoretic mobility shift assays. The binding reaction was
electrophoresed through a 5% native polyacrylamide gel in
0.5x TBE. Following overnight exposure of the gel, the
bands corresponding to the protein-DNA complex and free
DNA were excised from the gel, and the DNA was purified
by electroelution onto NA45 membranes (Schleicher &
Schuell) (2), subjected to 1 M piperidine cleavage, and
analyzed by electrophoresis through a 15% polyacrylamide-7 M urea sequencing gel.
The probes for ethylation interference analysis were modified on phosphates with N-ethyl-N-nitrosourea (Sigma), as
described by Siebenlist and Gilbert (36). The binding reactions, electrophoresis, and purification of the DNA from the
native polyacrylamide gels were performed as described for
methylation interference assays. Purified DNA from the
protein-DNA complex and free DNA bands from the mobility shift assay were cleaved by alkali (36), and the cleavage
products were analyzed by electrophoresis through a 15%
polyacrylamide-7 M urea sequencing gel.
RESULTS
Assay for MCREF-1 activity. We assayed for MCREF-1 by
its ability to bind specifically the LVb-core region in the
Moloney and Friend MLV enhancers by electrophoretic
mobility shift assays (12, 13, 37). The sequences of the
oligonucleotides that were used as probes and/or competitors are shown in Fig. 1 and Table 1. The probe is a 25-bp
synthetic oligonucleotide (LVb/core E) that contains the
wild-type LVb site and a mutated core site. Methylation
interference analyses showed that this mutation in the core
site (CCAAACAGGATATCT-iTGGTAAGCA -- CCAAAC
AGGATATC8TITGGTAAGCA) disrupts binding of CBF
(42) but does not affect MCREF-1 binding (28). The LVb/
core E probe enables us to more easily detect MCREF-1
above the background of abundant CBF in calf thymus
nuclear extracts. We performed competition assays on active fractions at each step of the purification with the
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unlabeled LVb/core E oligonucleotide and with the doublestranded LVb/core D oligonucleotide that contains mutations in two guanines in the LVb site (CCAAACAI
IATATCTGTGGTAAGCA). Together, competition with
the LVb/core E and LVb/core D oligonucleotides identifies
proteins that specifically bind sequences in the LVb site.
Partial purification of MCREF-1. An extract prepared from
calf thymus nuclei was first fractionated on a DE52 cellulose
column (Fig. 2A to C). Most of the MCREF-1 activity eluted
from the DE52 cellulose column between 60 and 150 mM
NaCl (fractions 57 to 65 [Fig. 2A and B]). There are two
predominant protein-DNA complexes generated from the
proteins in fractions 57 to 65 that appear to require sequences in the LVb site for binding (Fig. 2C). The MCREF-1
protein-DNA complex has a relatively low mobility (Fig. 2C,
lanes 1, 4, and 7, open circle). The second protein-DNA
complex has a much higher mobility (Fig. 2C, lane 4, solid
circle). We have not characterized the protein that generates
the higher-mobility protein-DNA complex and monitored
only the low-mobility MCREF-1 protein-DNA complex
throughout the purification.
The flowthrough fractions also contain proteins that bind
to the LVb/core E probe (fractions 19 to 33 [Fig. 2A and B]),
but MCREF-1 is a relatively minor component of this
activity (Fig. 2C, lanes 1 to 3). Most of the activity in
flowthrough fractions is not specific for the LVb site, since
the formation of the intense, diffuse protein-DNA complex
can be inhibited by the LVb/core D oligonucleotide (Fig. 2C,
lane 3). The amount of MCREF-1 activity in the flowthrough
fractions is difficult to quantify because of the high background of other proteins binding specifically or nonspecifically to the LVb/core E probe. Most of the binding activity
in fractions 69 to 85 is also not specific for sequences in the
LVb site (Fig. 2C, lanes 7 to 9), and only a small amount of
MCREF-1 is present in these fractions.
We pooled fractions 57 to 65 from the DE52 cellulose
column, which contain most of the MCREF-1 activity, and
dialyzed these pooled fractions against buffer B (50 mM
NaCi). Pooled fractions 57 to 65 from the DE52 cellulose
column were subsequently chromatographed on a heparinSepharose column (Fig. 2D to F). Most of the MCREF-1
activity eluted from the heparin-Sepharose column between
380 and 470 mM NaCl (fractions 79 to 91). A small amount of
MCREF-1 was present in flowthrough fractions 11 to 15 (Fig.
2E and F, lanes 1 to 3). Two proteins that gave rise to
higher-mobility protein-DNA complexes specific for the
LVb site also eluted from the heparin-Sepharose column in
fractions 79 to 89 and 91 to 97 (Fig. 2E). The higher-mobility
protein-DNA complex from fractions 91 to 97 (Fig. 2F, lanes
7 to 9, solid circle) has the same relative mobility as the
protein-DNA complex generated from fractions 57 to 65 of
the DE52 cellulose column (Fig. 2C, lanes 4 to 6, solid
circle). The other protein that specifically binds the LVb site
and elutes from the heparin-Sepharose column in fractions
79 to 89 (Fig. 2F, lanes 4 to 6, open triangle) cannot be
clearly seen in the pooled fractions from the DE52 cellulose
column.
We pooled fractions from the heparin-Sepharose column
containing most of the MCREF-1 activity (fractions 78 to 93)
and used these pooled fractions in all subsequent analyses.
We refer to these pooled fractions as the heparin-Sepharose
fraction. We achieved an approximately 18.7-fold purification of MCREF-1 following chromatography on both DE52
cellulose and heparin-Sepharose columns.
MCREF-1 recognizes sequences in both the LVb and core
sites. We performed a methylation interference analysis to
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characterize binding of MCREF-1 to sequences in the LVb/
core probe (Fig. 3). Methylation of guanines 8 and 9 on the
plus strand in the LVb site, guanine 6 in the minus strand in
the LVb site, and guanines 18 and 19 on the plus strand of
the core site interferes with MCREF-1 binding. This is
consistent with the consensus site defined by Manley et al.
(28) on the basis of a comparison of MCREF-1 binding sites.
The two pairs of guanines on the plus strand are separated by
8 bp, or one turn of the B-form DNA helix from guanines 8
and 9 to guanines 18 and 19. The MCREF-1 methylation
interference pattern is distinct from that generated by Ets-1,
Ets-2, or CBF (Fig. 3). Ets-1 and Ets-2 binding are disrupted
by methylation of guanines 8 and 9 on the plus strand and 6
and 14 on the minus strand. The contacts made by MCREF-1
in the core site (guanines 18 and 19) are outside of the
binding site for Ets-1 and Ets-2 (34). CBF contacts guanines
16, 18, and 19 on the plus strand in the core site and, unlike
MCREF-1, does not contact sequences in the LVb site (42).
Denaturation-renaturation analysis of MCREF-1. Previously identified proteins that bind to the LVb and core region
of the Moloney or SL3-3 MLV enhancers specifically recognize sequences in either the LVb site or the core site (21, 28,
34, 40-42). To determine whether the MCREF-1 proteinDNA complex comprises two distinct proteins, one binding
to the LVb site and the other binding to the core site, we

attempted to separate putative LVb and core binding proteins by SDS-PAGE. Proteins in the heparin-Sepharose
fraction were fractionated by electrophoresis through an
SDS-polyacrylamide gel. We cut the gel into 22 equal
4.2-mm slices from top to bottom, eluted the proteins from
each gel slice, subjected the proteins to a denaturationrenaturation regimen (16), and assayed the renatured proteins from each gel slice for binding to the LVb/core A probe
by electrophoretic mobility shift assay. We reasoned that if
MCREF-1 consists of two cooperatively binding proteins,
such as a member of the Ets protein family and CBF, then
proteins isolated from individual gel slices either should not
yield a protein-DNA complex or should generate proteinDNA complexes with higher mobilities than the relatively
low-mobility MCREF-1 protein-DNA complex. On the other
hand, if the MCREF-1 protein-DNA complex consists of a
single protein, or a multimeric protein comprising homologous subunits, then proteins isolated from a single gel slice
should give rise to a protein-DNA complex with the same
mobility and sequence specificity as the MCREF-1 proteinDNA complex generated by proteins in the heparinSepharose fraction prior to separation by SDS-PAGE.
Three adjacent slices from the SDS-polyacrylamide gel
contained proteins yielding a protein-DNA complex with a
mobility similar to that obtained with the heparin-Sepharose
fraction (Fig. 4A, gel slices 11 to 13). These proteins migrated in the SDS-polyacrylamide gel with an apparent
molecular mass of 50 to 70 kDa. We do not know whether
these are three distinct proteins or different proteolytic
breakdown products of a common larger protein. The minimal molecular mass for MCREF-1 (50 kDa) is greater than
that of the largest CBF polypeptide previously identified (35

kDa) (42).
We assayed for binding specificity of the renatured proteins by competition analysis with the LVb/core A oligonucleotide as a probe and a series of oligonucleotides containing mutations at one or more guanines in the LVb and core
sites to compete for binding of MCREF-1 to the LVb/core A
probe (LVb/core B to E [Fig. 1 and Table 1]). The competition pattern of the MCREF-1 protein-DNA complex from
the SDS-PAGE-fractionated and renatured proteins is indis-
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FIG. 2. Fractionation of MCREF-1. (A to C) Chromatography on DE52 cellulose. Nuclear extract was loaded onto a DE52 cellulose
column. The column was developed with a linear gradient of [NaCI] from 50 mM to 1.0 M. (A) DE52 cellulose column profile. Alternate
fractions were assayed for protein concentration, [NaCI], and MCREF-1 activity with the LVb/core E probe. The bracketed horizontal line
indicates the fractions that were pooled and loaded onto the next column. (B) Electrophoretic mobility shift assay of column fractions.
Fraction numbers are indicated on the bottom. Lanes: L, 10 pLl of nuclear extract; 1 to 91, 10 p.1 of elution fractions from the DE52 cellulose
column. (C) Competition analysis of binding activity in various fractions from the DE52 cellulose column. Lanes: 1 to 3, flowthrough fraction
29; 4 to 6, fraction 63, 7 to 9, fraction 69. The first lane for each fraction (1, 4, and 7) represents binding to the LVb/core E probe. The second
lane (2, 5, and 8) represents binding to the LVb/core E probe in the presence of 50 ng of unlabeled double-stranded LVb/core E
oligonucleotide. The third lane (3, 6, and 9) represents binding to the LVb/core E probe in the presence of 50 ng of unlabeled LVb/core D.
Open circle, low-mobility MCREF-1 protein-DNA complex; closed circle, position of a distinct higher-mobility LVb-specific protein-DNA
complex. (D to F) Chromatography on heparin-Sepharose. (D) Pooled fractions (57 to 65) from the DE52 cellulose column were dialyzed
against buffer B and loaded onto a heparin-Sepharose column. Alternate fractions were assayed for specific DNA binding activity, for protein
concentration, and for [NaCI]. The bracketed horizontal line indicates the pooled heparin-Sepharose fractions. (E) Electrophoretic mobility
shift assay of column fractions. Lanes: L, 3 ,ul of pooled DE52 fractions 57 to 65 that were loaded onto the column; 1 to 97, elution fractions
from the heparin-Sepharose column. (F) Competition analysis of binding activity in selected fractions from the heparin-Sepharose column.
Lanes: 1 to 3, flowthrough fraction 15; 4 to 6, fraction 83; 7 to 9, fraction 93. The first lane for each fraction (1, 4, and 7) represents binding
to the LVb/core E probe. The second lane (2, 5, and 8) represents binding to the LVb/core E probe in the presence of 50 ng of unlabeled
LVb/core E. The third lane (3, 6, and 9) represents binding to the LVb/core E probe in the presence of 50 ng of unlabeled LVb/core D. Open
circle, low-mobility MCREF-1 protein-DNA complex; closed circle and triangle, positions of other higher-mobility LVb-specific protein-DNA
complexes.
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FIG. 3. Methylation interference analysis of MCREF-1 on the
LVb/core A probe. (A) The autoradiogram of the methylation
interference assay is in the upper portion of the figure. Methylation
interference was performed with the heparin-Sepharose fraction on
methylated probe LVb/core A. Left panel, plus strand of the
LVb/core probe A; right panel, minus strand. Lanes C and F
correspond to the protein-DNA complex and free DNA bands,
respectively. Arrows show the methylated guanines specifically
depleted from the DNA in the protein-DNA complex. Circles in the
vertical sequence indicate the location of guanines whose methylation specifically inhibits MCREF-1 binding to the LVb/core A
probe. Closed circles (solid line) indicate complete interference;
broken circles (dashed lines) indicate partial interference. The
bottom portion of the figure summarizes the methylation interference results. The sequence is numbered 1 to 25 according to the 5'
end of the plus strand of the LVb/core A probe. Closed circles,
guanine contacts for MCREF-1; open circles, contacts for Ets-1
(34); open squares, contacts for CBF (42).

tinguishable from that of the MCREF-1 protein-DNA complex obtained from the heparin-Sepharose fraction (Fig. 4B).
Oligonucleotides with mutations in guanine 19 (plus strand,
LVb/core B), guanine 6 (minus strand, LVb/core C), or
guanines 8 and 9 (plus strand, LVb/core D) do not compete
effectively for binding of MCREF-1 to the LVb/core A
probe. An LVb-core oligonucleotide with a mutation in
guanine 16 (plus strand, LVb/core E) does compete for
binding of MCREF-1 to the LVb/core A probe. The competition pattern is consistent with the methylation interference
data (Fig. 3).
These results suggest that the MCREF-1 protein-DNA
complex results from the binding of a single monomeric
protein or a multimeric protein composed of homologous
subunits to sequences in both the LVb and core sites.
However, MCREF-1 could also be a heterodimeric protein
consisting of subunits with similar molecular weights.
MCREF-1 binds to multiple sites in both the Moloney and
Friend MLV enhancers. Binding of partially purified bovine
MCREF-1 to the LVb-core sequence can be inhibited by two
oligonucleotides from the Friend MLV enhancer containing
the FVa and FVbl sites (28). Here we extend this analysis to
show the direct binding of bovine MCREF-1 to the FVa and
FVbl sites and also to the corresponding regions in the
Moloney virus enhancer. Binding of MCREF-1 to the LVb/
core A probe can be specifically inhibited with oligonucleotides containing the FVa and FVbl sequences from the
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FIG. 4. Denaturation-renaturation analysis of MCREF-1. (A)
Electrophoretic mobility shift assay of MCREF-1 following fractionation by SDS-PAGE. Proteins were eluted from SDS-polyacrylamide gel slices and subjected to a denaturation-renaturation regimen, as described in Materials and Methods. Renatured proteins
were assayed for binding to the LVb/core A probe. The numbers on
the top of each lane correspond to the gel slice (from top to bottom)
from the SDS-polyacrylamide gel. Numbers on the bottom represent
the location of molecular weight markers in the SDS-polyacrylamide
gel (proteins eluted from gel slice 22 were not assayed). (B)
Comparison of the sequence specificity of MCREF-1 from the
heparin-Sepharose fraction to that of the renatured polypeptides.
Binding to the LVb/core A probe was conducted in the absence
(vertical line) or presence of 50 ng (500-fold molar excess) of
LVb/core A, B, C, D, or E competitor oligonucleotides. The protein
sample (either heparin-Sepharose or proteins from gel slices 12 and
13) is indicated on the bottom. The binding specificity of the protein
from gel slice 11 was not analyzed.

sponding regions from the Moloney enhancer, MVa and
MVb (Fig. SA). MCREF-1 binding to the LVb/core A probe
can also be inhibited by the Moloney virus GC-rich region
located 3' to the enhancer direct repeat (MVc [Fig. SA]) and
less effectively by the corresponding region from the Friend
virus (FVc [Fig. 5A]). The Friend virus FVa and FVbl
oligonucleotides appear to be the most effective competitors
for MCREF-1 binding, the MVb and FVc oligonucleotides
appear to be the least effective competitors, and a highaffinity nuclear factor 1 (NF-1) binding site from the adenovirus type 2 origin of replication (Ad-NFl) (7) does not
compete for MCREF-1 binding to the LVb/core A probe.
We performed binding and competition analysis on the
LVb/core A probe with a purified bacterially expressed
14-kDa N-terminal truncated form of Ets-1, kindly provided
by Barbara Graves (34). The 14-kDa Ets-1 protein bound to
the LVb/core A probe, and its binding could be inhibited by
LVb-core probes with mutations in the core sites (LVb/core
B and LVb/core E) and by the FVa and MVa oligonucle-
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FIG. 5. Binding of MCREF-1 to sequences in the Friend and Moloney MLV enhancers. (A) Binding to the LVb-core A probe in the
absence (vertical line) or presence of increasing amounts (1, 5, 10, or 50 ng) of LVb/core A, FVa, FVb1, MVa, MVb, FVc, MVc, and Ad-NF1
competitor oligonucleotides. The titration of increasing amounts of competitor DNA is indicated by the horizontal triangle. (B) Binding and
competition on the FVa probe. Reaction conditions are as described for panel A, with 50 ng of competitor oligonucleotides. (C) Binding and
competition on the FVb1 probe. (D) Binding to the MVa probe. (E) Binding to the MVb probe.

the LVb site (LVb/core C and LVb/core D) or with the FVbl
oligonucleotide (data not shown). This pattern of competition is distinct from that obtained for MCREF-1 and further
supports the conclusion that MCREF-1 and Ets-1 are distinct proteins.
We assayed for direct binding of MCREF-1 to the Friend
virus FVa and FVbl probes and the Moloney virus MVa and
MVb oligonucleotide probes. The concentration of oligonucleotide competitors used in these experiments (Fig. 5B to
E) is equivalent to the greatest amount (50 ng) used for the
LVb/core A probe (Fig. 5A). MCREF-1 generates a proteinDNA complex with a similar mobility on the FVa (Fig. 5B)
and FVbl (Fig. 5C) probes that can be specifically inhibited
with the FVa, FVbl, LVb/core A, LVb/core E, MVa, and
MVc oligonucleotides but not with the LVb/core B, C, or D
oligonucleotide, the Ad-NFl site, or the MVb or FVc
oligonucleotide. Although 50 ng of either the MVb or the
FVc oligonucleotide inhibits MCREF-1 binding to the LVb/
core A probe (Fig. 5A), 50 ng of the MVb and FVc
oligonucleotides does not inhibit MCREF-1 binding to the
apparently higher-affinity FVa and FVbl probes.
The MCREF-1 protein-DNA complex on the MVa and
MVb probes is obscured by NF1 activity in the heparinSepharose fraction, which binds to the NF1 sites present in
these two probes (Fig. SD and E). Inclusion of the unlabeled
Ad2-NF1 oligonucleotide in the binding reaction mixture
effectively inhibits NF-1 binding, enabling us to visualize the
MCREF-1 protein-DNA complex. The competition pattern
of the MCREF-1 protein-DNA complex on the MVa probe is

difficult to discern because of the presence of a residual
protein-DNA complex specific for the MVa probe that
migrates at a mobility similar to that of MCREF-1. However,
it is clear that the MCREF-1 protein-DNA complex on the
MVa probe cannot be inhibited by the Ad-NF1, LVb/core B,
LVb/core C, or LVb/core D oligonucleotide. On the MVb
probe, which contains a relatively low-affinity binding site
for MCREF-1, the competition pattern is similar to that
obtained with the LVb/core A probe. Similar results were
also obtained with the MVc probe (42a).
Characterization of MCREF-1 binding sites. We identified
the guanine contacts for MCREF-1 on its various binding
sites by methylation interference analysis (Fig. 6). We were
not able to obtain a satisfactory methylation interference on
the MVb probe because of its relatively low affinity for
MCREF-1. Comparison of the contacts made by MCREF-1
on the LVb/core A, FVa, MVa, FVbl, and MVc probes
(Fig. 6B) reveals several common features, some of which
were noted previously (28, 29). (i) Binding of MCREF-1 to
each CNGG repeat is generally characterized by a partial
interference on the first guanine and a complete interference
on the second guanine. (ii) The first CNGG repeat is separated by 6 bp from the second CNGG repeat (10 bp from
center to center, or one turn of the B-form DNA helix). The
6-bp spacing between the CNGG repeats appears to be
critical for binding. Note that the MVc probe contains, in
addition to the bona fide MCREF-1 binding site, two consensus CNGG sequences separated by 7 instead of 6 bp
(CTGGACCGCATCTIGG, positions 3 to 17 [Fig. 6B]).
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FIG. 6. Methylation interference assay on the FVa, MVa, FVbl,
and MVc oligonucleotides. (A) Binding reactions were performed as
described in the legend to Fig. 3. Left panel for each probe, plus
strand; right panel, minus strand. Lanes C and F correspond to the
protein-DNA complex and free DNA bands, respectively. Arrowheads indicate the location of guanines whose methylation specifically inhibits the binding of MCREF-1. The sideways exclamation
points indicate enhanced cleavage seen in the protein-DNA complex. The numbers on the side of each lane correspond the 5' end of
the plus strand of the probe. (B) Summary of methylation interference results. Rectangles indicate the two CNGG direct repeats in
the MCREF-1 binding site (1 and 2). Closed circles, guanine
contacts for MCREF-1 at which complete interference was seen;
open circles, partial interference; exclamation points, positions of
enhanced cleavage. The MVc probe is shown in reverse orientation,
with the plus strand on the bottom. The numbers indicate the
position of the 5' end of each probe relative to its orientation in the
viral genome. The underlined sequence in the MVc probe indicates
the third CNGG repeat.

MCREF-1 does not bind to this site but instead binds to a
site consisting of a 3' CNGG sequence separated by 6 bp
from a sequence that deviates from the CNGG consensus
(GATGAGGJXCTGG, positions 14 to 27). (iii) In those
sites that contain a cytosine at the first position of the CNGG
repeat (CNGGN&CNGG), the guanine on the other strand at
that position is also a contact for MCREF-1. (iv) In CNGG
sequences that are directly followed by a guanine (FVa,
position 15; MVa, position 35; FVbl, positions 10 and 20
[minus strand]), modification of this guanine results in enhanced binding by MCREF-1 or alternatively enhanced
cleavage by an endonuclease in the partially purified
MCREF-1 preparation. (v) Deviation from the consensus
CNGG sequence in one repeat of an MCREF-1 binding site
is compatible with MCREF-1 binding if the other CNGG
repeat conforms to the consensus. For example, the
MCREF-1 site in the MVa oligonucleotide deviates from the

1983

consensus CNGG sequence at one position in the first repeat
(ATGGN6CAGG). In contrast, when the same C -- A
transversion is introduced into the LVb-core site to generate
the LVb/core C oligonucleotide (AAGGN6GTGG) it disrupts
MCREF-1 binding. Unlike the MVa oligonucleotide, the
LVb/core C oligonucleotide does not contain a consensus
CNGG sequence in the second repeat.
Dimethylsulfate methylates DNA on N-7 of guanine,
which projects into the major groove, and N-3 of adenine in
the minor groove. Methylation can affect protein binding by
disrupting the formation of a hydrogen bond between the
protein and the N-7 or N-3 atom of guanine or adenine or by
sterically interfering with protein binding because of the
introduction of a bulky methyl group. Methylation can also
disrupt protein binding by indirect effects, for example, by
altering the conformation of DNA or increasing the free
energy required for the DNA to assume a particular conformation in the protein-DNA complex. The extensive contacts
made by MCREF-1, particularly within the N6 spacer between the conserved CNGG sequences, probably results
from a combination of these effects of methylation.
We only note the methylated guanines that interfere with
MCREF-1 binding in Fig. 6. Several methylated adenines
also interfere with MCREF-1 binding. Adenine contacts
made by MCREF-1 in the FVa site are summarized in Fig. 8.
We identified the phosphate contacts made by MCREF-1
on the DNA backbone in the LVb/core, FVa, and FVbl, and
MVc probes by ethylation interference (36) (Fig. 7). Ethylation of phosphates can sterically interfere with binding of the
protein or can disrupt electrostatic interactions between the
protein and the negatively charged phosphates on the DNA
backbone. MCREF-1 contacts between 2 and 5 phosphates
on both strands in each CNGG sequence. The 5' and 3'
boundaries of the phosphate interference pattern are difficult
to determine precisely, since the backbone cleavage can
occur on either side of the phosphate (36). The multiple
cleavage products resolve from each other when these short
oligonucleotide probes are electrophoresed through denaturing polyacrylamide gels and thus appear as several bands.
Despite the difficulty in determining the precise boundaries
of the phosphate interference pattern, we can conclude that
the pattern is centered over the CNGG sequences and that it
is staggered in the 3' direction, characteristic of proteins that
bind in the minor groove of DNA.

DISCUSSION
We have partially purified and further characterized the
binding properties of MCREF-1, a protein that binds multiple sites on the Friend and Moloney MLV enhancers.
Comparison of the sequence of the binding sites for
MCREF-1 and the methylation and ethylation interference
data suggest that the MCREF-1 binding site consists of a
direct repeat of the sequence CNGG, with the two CNGG
sequences separated by one complete turn of the B-form
DNA helix. Independent mutations in each of the CNGG
repeats disrupt binding of MCREF-1; therefore, the protein
must contact both of the CNGG repeats simultaneously. The
MCREF-1 protein-DNA complex can be generated from
proteins isolated from single slices from an SDS-polyacrylamide gel. This indicates that MCREF-1 proteins are either
single subunit proteins whose binding site spans one turn of
the DNA helix or that MCREF-1 proteins are multimeric
proteins consisting of subunits with similar sizes.
The LVb site forms the 3' CNGG repeat in the FVa site
and the 5' CNGG repeat in the LVb-core site. MCREF-1
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could theoretically form multimers and bind all three CNGG
repeats in the FVa and LVb-core sites simultaneously or

could preferentially bind either the FVa or LVb-core sites.
The latter situation seems to be the case. When an oligonucleotide containing all three CNGG repeats in the FVa and
LVb-core sites (CTGGGCCAAACAGGATATCTGTIGG) is
used in methylation interference assays, purine contacts are
found only in the higher-affinity FVa site (CTGGGCCAAA
CAGGATATCTGTGG [data not shown]). Mutation of the 5'
repeat in the FVa site (ClI[GCCAAACAGGATATCT
GTGG) shifts the MCREF-1 contacts to the LVb-core site
(data not shown).
Ethylation interference data suggest that MCREF-1 binds
DNA primarily across the minor groove. This can be seen
most clearly on a display of the chemical interference data
on a B-form DNA helix (Fig. 8). Depicted are the MCREF-1
contacts on the FVa oligonucleotide derived from the Friend
MLV enhancer. In this model, we designate the side of the
helix facing the reader as the front face. MCREF-1 contacts
phosphates in each CNGG sequence across two adjacent
minor grooves primarily on the front face of the DNA helix.
Both CNGG sequences are within the regions of phosphates
contacted by the protein, which supports the derived consensus sequence of a direct repeat separated by a 6-bp
spacer (CNGGN6CNGG). The degenerate 6-bp spacer be-

tween the CNGG repeats (positions 15 to 20 in Fig. 8) is in
the major groove on the front face of the helix, between the
areas of minor groove contacts. MCREF-1 contacts one
guanine in the major groove in this 6-bp spacer in the FVa
probe (position 16) and one guanine 5' to the first CNGG
sequence (position 10). MCREF-1 contacts guanines in the
major groove in the 6-bp spacer between the CNGG repeats
in the MVa, FVbl, and MVc probes. MCREF-1 also contacts guanines flanking the 5' or 3' side of the CNGG repeats
in the FVa, FVbl, and MVc probes. The degeneracy of the
DNA sequence between and flanking the CNGG repeats
suggests that MCREF-1 does not directly read the base pair
sequences in the major groove in these regions.
Methylation of adenines in the minor groove in the putative half-sites also interferes with MCREF-1 binding, which
is consistent with the hypothesis that MCREF-1 binds in the
minor groove. However, adenine interference data are inconclusive, since the structure of DNA in the more narrow
minor groove is more easily perturbed by the introduction of
a bulky methyl group, which could indirectly disrupt

MCREF-1 binding.
Although the ethylation interference pattern suggests that
MCREF-1 docks primarily across two adjacent minor
grooves on the front face of the B-form DNA helix, this
model does not completely account for all the chemical
interference data. The methylation interference pattern indicates that MCREF-1 also contacts three guanines in the
major groove on the opposite side (the back face) of the helix
within the CNGG repeats. To accommodate both the gua-

VOL. 67, 1993

MAMMALIAN TYPE C RETROVIRAL ENHANCER FACTOR 1

3'
5'

3'

C

G

10 G

15

C

C

G

T
G
G

A
C

C

G

C

G
G
T

C
C

20

A
A
A

T
T

G
T

C

A
G
G
25 A
3'

C
C

T
5'

3'

FIG. 8. Summary of guanine, adenine, and phosphate contacts
made by MCREF-1 on the FVa probe from the Friend MLV
enhancer. Open circles on the B-form DNA helix represent the
phosphate contacts made by MCREF-1. Squares within the base
pair ladder indicate the guanine and adenine contacts. The sequence
on the left side of the helix represents the plus strand of the probe;
the sequence on the right side represents the minus strand. Vertical
bars next to the sequence indicate the position of the CNGG
sequences.

nine and phosphate contacts, we propose that MCREF-1
docks primarily on the front face of the helix, but some part
of the MCREF-1 protein reaches around the back of the
helix to contact guanines in the major groove.
The chemical interference pattern of MCREF-1 is unique
from that of other DNA binding proteins that have been
analyzed, including the Ets family of proteins, the yeast
protein GAL4, the homeodomain proteins, bZIP proteins as
represented by C/EBP, and the helix-turn-helix proteins.
The Ets proteins bind one major groove on one helix face
(34). GALA binds two successive major grooves on one helix
face (30). The homeodomain proteins bind one major groove
and one adjacent minor groove on one face of the helix (1,
24, 45). Lambda repressor, which is a helix-turn-helix protein, binds two successive major grooves on one helix face
(19, 22). C/EBP contacts a major groove for one full helical
turn (33). Ethylation interference indicates that MCREF-1
binds two successive minor grooves on one helix face. Since
the various members of a family of DNA binding proteins
interact with the DNA helix in a characteristic manner,
MCREF-1 does not appear to belong to the Ets, homeodomain, bZIP, or helix-turn-helix family of proteins. Therefore, MCREF-1 may represent a new protein structure that
binds DNA.
MCREF-1 binding sites are found in a large number of
mammalian type C retrovirus enhancers. The MCREF-1 site
in the LVb-core region is conserved in at least 32 of 35
independent retrovirus isolates. The MCREF-1 site immediately 5' to and including the LVb site (corresponding to the
FVa site in the Friend enhancer) is also conserved in a
significant number of viruses, although there are several
variations in the sequence of the site: CTGGGCCAAA
CAGG (Friend MLV, second copy of the direct repeat),
CCGGGCCAAACAGG (gibbon ape leukemia virus, San
Francisco isolate), CAG GCCAAACAGG (simian sarcoma

virus), ATGGGCCAAACAG.

(Harvey, Moloney, and my-

1985

eloproliferative sarcoma viruses; Moloney and Abelson
MLV), and TTGGGCCAAACAGG (Rauscher mink cell
focus-forming virus, Rauscher spleen focus-forming virus,
NS6MCF virus, Friend spleen focus-forming virus [polycythemia inducing], first copy of the Friend MLV enhancer,
Lake Casitas brain E neurotropic virus, amphotropic murine
retrovirus clone 4070a, Ho wild mouse leukemia virus,
Rauscher spleen focus-forming virus) (see reference 14 for
sequence alignment). All of the sequences in the half-sites
(CTGG, CCGG, CAGG, ATGG, and TTGG) have been
found in bona fide MCREF-1 binding sites (28, 29; this
paper). Eight additional viruses contain the sequence
TAGGGCCAAACAGG. Since a T is permissible in either of
the first two positions in other MCREF-1 binding sites, we
predict that MCREF-1 will also bind to this site. MCREF-1
may therefore contribute to the transcription of a large
number of mammalian type C retroviruses in vivo. Mutations in the LVb site in the Moloney virus which should
disrupt MCREF-1 binding increased the latent period of
disease caused by the Moloney virus (39). However, this
mutation would disrupt not only MCREF-1 binding but also
binding of LVt and the proteins in the Ets family. No
mutations in this MCREF-1 site that would selectively
disrupt MCREF-1 binding have yet been analyzed.
What might be the role of MCREF-1 in specifying the
pathogenic phenotypes conferred by mammalian type C
retrovirus enhancers? Simply the presence or absence of
binding sites for MCREF-1 cannot be a determining factor,
since binding sites for MCREF-1 are distributed in multiple
locations on many retrovirus enhancers. If MCREF-1 does
influence pathogenesis by these enhancers, then the mechanism must involve the number or distribution of MCREF-1
binding sites on these enhancers, the relative affinity of
MCREF-1 for these sites, and/or the potential for interaction
with other proteins on the enhancer. Interaction with other
proteins could take the form of cooperative binding or steric
interference between MCREF-1 and proteins binding to
overlapping or adjacent sites.
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